FOLH1 and neoplasm: Recently, we evaluated if 177Lu-PSMA could become a potential effective MDT for patients with mHSPC harboring low tumor load (≤ 10 metastases on [68Ga]Ga-PSMA-PET imaging [PSMA-PET]) in a prospective pilot study (10).